(Q36950052)

17 August 2017

1 reference

title

Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma (English)

1 reference

17 August 2017

1

Avichai Shimoni

1 reference

17 August 2017

Arnon Nagler

2

1 reference

17 August 2017

publication date

1 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

48

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

2110-2120

1 reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Radioimmunotherapy of non-Hodgkin lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Rituximab: mechanism of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

131I-tositumomab therapy as initial treatment for follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

The graft-versus-lymphoma effect: clinical review and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190701573273

10.1080/10428190701573273

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference